Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: J Immunol. 2011 Aug 3;187(5):2602–2616. doi: 10.4049/jimmunol.1101004

Figure 1. Novel adjuvants can improve the immunogenicity of protein vaccines.

Figure 1

C57BL/6 mice (n= 6 / group) were immunized i.m. with 20μg of OVA formulated in adjuvant. Total IgG titers were measured in the serum in response to OVA protein by ELISA. (A) IgG titers measured two weeks after each immunization (Imx). Median responses are shown with range. ** p<0.01 by two-way ANOVA with Bonferroni’s multiple comparison post-test. (B) IgG titers measured two weeks after the third immunization. Median responses are shown. T cell responses were assayed in the blood against the (C) pooled H-2b CD4+ T cell epitopes and (D) the H-2b CD8+ T cell epitope present in OVA. Median responses are shown. The dotted line indicates the threshold for responses above background in (A) and (B).